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What is synergy? The Saariselkä
agreement revisited
Jing Tang*, Krister Wennerberg* and Tero Aittokallio *
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
Many biological or chemical agents when combined interact with each other and produce
a synergistic response that cannot be predicted based on the single agent responses
alone. However, depending on the postulated null hypothesis of non-interaction, one
may end up in different interpretations of synergy. Two popular reference models for
null hypothesis include the Bliss independence model and the Loewe additivity model,
each of which is formulated from different perspectives. During the last century, there
has been an intensive debate on the suitability of these synergy models, both of which
are theoretically justified and also in practice supported by different schools of scientists.
More than 20 years ago, there was a community effort to make a consensus on the
terminology one should use when claiming synergy. The agreement was formulated at
a conference held in Saariselkä, Finland in 1992, stating that one should use the terms
Bliss synergy or Loewe synergy to avoid ambiguity in the underlying models. We review
the theoretical relationships between these models and argue that one should combine
the advantages of both models to provide a more consistent definition of synergy and
antagonism.
Keywords: definition of synergy, drug combinations, Bliss and Loewe models, interaction barometer, consensus
agreement
Introduction
Evaluation of interaction effects between biologically active agents has become an important topic
in many disciplines, including pharmacology (Cokol et al., 2011; Miller et al., 2013; Chevereau and
Bollenbach, 2015), biochemistry (Hu et al., 2011; Zhang and Viikari, 2014; Bunterngsook et al.,
2015), and environmental sciences (Darling and Côté, 2008; Piggott et al., 2015). The interaction
between multiple agents is often classified as either synergistic or antagonistic, depending on
how much the observed combination response differs from the expected response under the null
hypothesis that the two agents are non-interacting.Multiple referencemodels have been formulated
based on a distinctive set of empirical or biological assumptions (see e.g., Lehár et al., 2009).
These assumptions, albeit difficult to validate a priori due to the lack of precise knowledge of the
mechanisms of action, are often justifiable as long as they provide biologically plausible reasoning
about the nature of non-interaction. However, the inherent differences in the model assumptions
have inevitably led to inconsistency in the quantification of the degree of interaction, contributing
to a major source of confusion and controversy on the definitions of synergy and antagonism.
The Saariselkä agreement, proposed more than 20 years ago, aimed at reaching a consensus on
the terminology for characterizing the degree of interaction (Greco et al., 1992). Acknowledging
the theoretical background of the major competing models, the Saariselkä agreement admitted
that there is no single universally best reference model. Rather than continuing the debate on the
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appropriateness of the model assumptions, the agreement
called for a compromise between the advocates of the models,
and proposed a practical guideline for reporting synergy or
antagonism, where the underlying reference model should be
explicitly described to avoid any ambiguity.
The Two Reference Models
For the rest of the review, we will use drug combination as an
example of interaction data. A drug’s effect y is often measured
at a certain dose x as the percentage of biological response, i.e.,
x > 0, 0 < y < 1. Let us consider that, drug 1 at dose x1
produces a response y1 and drug 2 at dose x2 produces a response
y2. Next, we combine the two drugs at the dose pair (x1, x2)
and observe a combination response yc. To quantify the degree
of drug interaction, we need to formulate a reference model to
answer the following question: if there is no interaction between
the drugs, what would be the expected combination response
yEXP at (x1, x2)? So far, two major reference model classes have
been proposed, the Bliss independence model (Bliss, 1939) and
the Loewe additivity model (Loewe, 1953). While each having its
own logical basis, the underlying assumptions behind these two
models are relatively distinct.
The Bliss independence model adopts a probabilistic
perspective by treating a drug combination under non-
interaction as a joint action of independent, yet competing
perturbations by the individual drugs. Such a probabilistic
independence allows the expected combination response to be
computed as the product of the individual drug responses:
yBLISS = y1 + (1− y1)y2 = y1 + y2 − y1y2. (1)
An observed combination response greater or smaller than
yBLISS can be interpreted as a departure from the probabilistic
independence, which thus implies an interaction between the two
drugs. The Loewe additivity model, on the other hand, requires
additional information about the dose-response relationships of
the individual drugs. Namely, let y = f1(x) and y = f2(x) be
the dose-response functions for drug 1 and drug 2, respectively.
Then the doses at which each drug alone produces the expected
response yLOEWE can be represented as, f
−1
1 (yLOEWE) and
f−12 (yLOEWE), where f
−1 is an inverse function which maps the
response y back to the dose x. Formally, the Loewe additivity
model states that yLOEWE must satisfy:
x1
f−11 (yLOEWE)
+
x2
f−12 (yLOEWE)
= 1. (2)
The rationale behind Equation (2) is to fit non-interaction
to the so-called sham experiment scenario, where a drug is
combined with itself, that is, f1(x) = f2(x). According to
Equation (2), one can derive yLOEWE = f (x1 + x2) for the
sham experiment, reflecting the intuition that combining two
drugs of the same type should induce neither synergy nor
antagonism.
The Saariselkä Agreement
The assumptions and performance of the two reference models
have been compared and discussed in many review articles (e.g.,
Berenbaum, 1989; Greco et al., 1995; Chou, 2006; Lee, 2010; Zhao
et al., 2010). There have been attempts to distinguish the Bliss and
Loewe models in terms of mechanistic implications (Shafer et al.,
2008; Laskey and Siliciano, 2014; Chevereau and Bollenbach,
2015). The Bliss independence model is expected to hold true for
non-interacting drugs that elicit their responses independently,
e.g., by targeting separate pathways. Loewe additivity, in contrast,
is more compatible with the case where the drugs have similar
modes of action on the same targets or pathways. However,
little is known about whether such mechanistic justifications
for the Bliss and Loewe models reflect the reality. Further,
with increasing understanding of drugs’ modes of action,
any “previously unexpected” interaction effect becomes more
expected, whichmakes the referencemodels totally dependent on
the temporal state of knowledge. As pointed out in the Saariselkä
agreement (Greco et al., 1992), and also by many others, neither
Loewe additivity nor Bliss independence is necessarily reflecting
the expected modes of action of a drug combination (Fitzgerald
et al., 2006; Yeh et al., 2006; Breitinger, 2012). Rather, Loewe
and Bliss models should be used as data exploratory approaches,
with a major purpose to identify potential synergistic drug
combinations that warrant further mechanistic investigation, but
not the other way around, i.e., using the mechanistic evidence to
determine which reference model is more appropriate.
After reaching the common understanding on the model
assumptions, the Saariselkä agreement allowed the researchers
for the flexibility to choose a preferred reference model
to evaluate interactions of multiple agents, with the only
precondition that the names of the specific models need to be
explicitly reported. Namely, depending on which model is used, a
combination response greater or less than yEXP will be termed
as Loewe synergy, Loewe antagonism, Bliss synergy or Bliss
antagonism, respectively. Following these recommendations, the
controversy over the definitions of synergy and antagonism
seemed subsided. More recently, a variety of interaction
assessment methods have been further developed and applied
to a wide range of biological research fields. Notably, most
of these methods can be traced back to the two basic model
classes. For example, variants of the Loewe additive model
include combination index (Lee et al., 2007; Chou, 2010),
isobologram analysis (Tallarida, 2006) and response surface
models (Greco et al., 1995; Kong and Lee, 2006); variants of
the Bliss independence model include various synergy contour
approaches (Fitzgerald et al., 2006; Zhao et al., 2014).
What is Synergy?
Paradoxically, even with the clear distinction that has been made
between the reference models, we feel that the fundamental
question still remains unanswered, if not becoming even more
serious:What is synergy after all? Since the expected combination
responses yBLISS and yLOEWE most often are not identical
(Berenbaum, 1989), choosing the model to use has become
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a practical burden for a researcher who tries to draw solid
biological conclusions out from the data. Due to the lack of
practical guidelines, the model selection has become a personal
preference or largely a convention that has been followed in a
particular research field without clear reasons (Lee et al., 2007;
Zhao et al., 2014). There has been a tendency to favor a model
that yields a lower expected combination response, as it results
in a higher likelihood of detecting stronger synergy. To make
matters even worse, there has been often a dilemma when a
drug combination is classified as synergistic according to one
model but antagonistic according to the other (Cokol et al., 2011).
The Saariselkä agreement, unfortunately, seem to have failed to
provide any recommendations for solving these practical issues.
What the Saariselkä agreement achieved was a compromise
for accepting individualized claims, but the ultimate aim to
advance the consensus knowledge on the degree of interaction
has remained largely missing.
To ease the model selection burden, we propose here the use
of new terminology that incorporates both of the two reference
models, together with the single drug responses, to distinguish
non-interaction, synergy and antagonism. With simple algebra,
one can show that max(y1, y2) ≤ yBLISS. For the Loewe
additivity model with a monotonically increasing dose-response
relation, one can also show that max(y1, y2) ≤ yLOEWE. We
note that, max(y1, y2) is also the expected response from a
popular referencemodel, called highest single agent (HSA)model
(Berenbaum, 1989). If the combination response yc is lower
than max(y1, y2), then one would intuitively infer antagonism.
Therefore, we may use max(y1, y2), to distinguish antagonism
from non-interaction. Similarly, one can use the response of the
less effective single drug, that is min(y1, y2), to further distinguish
between weak and strong antagonisms. For distinguishing
synergy from non-interaction the answer is less obvious, as it
depends on the comparison between yBLISS and yLOEWE. There
has been considerable interest in the mathematical relationships
between the Bliss independence and the Loewe additivity models
to understand how much difference in the characterization of
drug interaction one can expect when choosing one model
over another (see e.g., Goldoni and Johansson, 2007). In
particular, two authors of the Saariselkä agreement have reported
results from such comparisons (Drescher and Boedeker, 1995;
Dressler et al., 1999). They showed that yLOEWE > yBLISS is
generally observed for very steep dose-response curves, while
yLOEWE < yBLISS when the curves become more flat. Since,
yBLISS and yLOEWE differ in a complex way depending on the
parameterization of the dose-response functions, we propose
two cut-offs, min(yBLISS, yLOEWE) and max(yBLISS, yLOEWE), for
characterizing synergistic combinations. We reason that the
consistency between the Bliss independence and the Loewe
additivity models should be indicative of the degree of synergy:
If both the Bliss model and the Loewe model classify a drug
combination as synergistic, that is, yc > max(yBLISS, yLOEWE),
then we call it a strong synergy; If the combination is
classified as synergistic according to one model only, that is,
min(yBLISS, yLOEWE) < yc < max(yBLISS, yLOEWE), then it
is called weak synergy. Finally, non-interacting drugs have
max(y1, y2) < yc < min(yBLISS, yLOEWE), reflecting our
view that non-interaction should also be defined similarly
as a range, rather than a single point as in the individual
reference models. Given such a classification, one may continue
to develop statistical testing methods for evaluation of its
significance for replicate data. To facilitate better understanding
of these definitions, we designed an interaction barometer
that enables a systematic comparison of these proposed
interaction terms along an axis of drug combination response yc
(Figure 1).
The benefits of adopting the proposed terminology for the
degree of interaction are two-fold. First, the definitions of synergy
and antagonism are based on a simultaneous evaluation of the
two reference models, as well as the individual drug responses.
Such a data-driven approach avoids any pre-defined preference
either for the Bliss independence or Loewe additivity when
characterizing drug interactions, and thus it minimizes the biases
toward either of the models. This is consistent with the idea that
any synergy model should be treated as an exploratory ranking
statistic for prioritization of the most potent combinations for
further evaluation, rather than a “true model” for explaining
synergy or antagonism mechanisms. Further, this terminology
enables a more intuitive definition of non-interaction, under
which the combination response may be higher than the single
drug response, but not as high as the expected responses from the
Bliss independence and the Loewe additivity models. Note that a
drug combination falling into such an interval would be classified
as antagonistic according to both of the two models, but since
it produces a higher response than the single drugs, one would
rather characterize it as an additive effect or non-interaction. For
the sake of clarity, we would call it non-interaction, and in fact
discourage the terms additive or additivity since these may be
confused with the additivity implicated by the Loewe additivity
model. The interval of non-interaction shown in Figure 1 is
positioned at the center of the barometer as a gray zone for those
drug combinations with no clear evidence in support of either
synergy or antagonism.
Secondly, the different interaction terms are positioned along
the common response axis (e.g., measured as the percentage
inhibitions of cell growth), which makes it easier to relate
the degree of drug interaction with its outcome in the drug
response. With the proposed interaction barometer (Figure 1),
one can immediately tell the differences between the drug
combination response yc and the responses of individual
drugs (y1, y2), as well as the expected combination responses
(yBLISS, yLOEWE) based on the two reference models. The
clear correspondence between the degree of synergy and the
combination response is in many ways superior to the use
of an interaction index, such as combination index or other
similar approaches (see e.g., Lee et al., 2007; Lee, 2010), which
tend to be less obvious to interpret in terms of response
boosting. For example, a combination index of 0.1 has been
considered as a very strong synergy by Chou (2006), but how
much extra response the synergy can produce for the drug
combination is difficult to tell. In contrast, with the interaction
barometer one can easily visualize the levels of boosted
response of the combination compared to the single drugs or
reference models. From the model development perspective,
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FIGURE 1 | The proposed terminology for classifying drug interactions. Using the interaction barometer allows a direct comparison between
different drug combinations in terms of their degrees of interaction as well as their combination responses. If the observed drug combination
effect yc is lower than the maximum single drug effect max(y1, y2 ) but higher than the minimum effect min(y1, y2 ), then the combination is
called weak antagonism; if yc < min(y1, y2 ) it is called strong antagonism. To classify synergy, we consider the Bliss and Loewe models, with the
expected effects denoted as yBLISS and yLOEWE, respectively. If max(y1, y2 ) < yc < min(yBLISS, yLOEWE), then we call the combination as
non-interaction; if yHSA < yc < min(yBLISS, yLOEWE ) it is called weak synergy, and for yc > max(yBLISS, yLOEWE ) strong synergy.
the graphical representation of the competing reference models
in the interaction barometer may facilitate a more systematic
comparison among different approaches. For example, when new
reference models are introduced, one can always position its
expected combination response onto the barometer to enable
better understanding of its relationships with the existing
models.
Synergy vs. Efficacy
So far, we have merely discussed about the assessment of
drug interactions using the difference between the observed
combination response and its theoretical expectation, i.e.,
yc − yEXP, to classify a drug combination as synergistic or
antagonistic. However, a drug combination can be also classified
as either effective or ineffective based solely on its actual
combination response yc. It is important not to confuse these
two concepts, synergy and efficacy, as the nomenclatures are
related but should not be treated the same. Synergy is a measure
of the degree of drug interaction, while efficacy is a measure
of phenotypic response of a drug combination. It is possible
that a drug combination is highly synergistic, while its actual
response may be insufficient to reach therapeutic efficacy. On
the other hand, a drug combination that exhibits strong response
does not necessarily imply a synergistic interaction. For instance,
only one of its component drugs may produce the response,
while the other one is simply lowering the adverse effect of the
first drug without affecting its on-target activity. In preclinical
testing, a drug combination with strong synergy and efficacy
should be prioritized for further mechanistic investigation, with
an additional requirement of tolerable toxicity profile (Fitzgerald
et al., 2006). Accordingly, the dosages of a drug combination are
also important factor for clinical feasibility and for maintaining
acceptable side effects. For instance, the concept of therapeutic
synergy compares the therapeutic windows of the single agents to
that of their combinations, instead of using compound efficacies
alone (Kashif et al., 2014). However, the main focus of this
review was the definition of synergistic interaction, and we refer
those readers interested in the therapeutic significance of synergy
in drug discovery to previous reviews (Fitzgerald et al., 2006;
Sucher, 2014).
Conclusion
The definition of synergistic interaction is still under debate.
After a careful investigation of the Bliss independence model and
the Loewe additivity model, we argue that, without jeopardizing
the validity of both models, a more consistent terminology
for classifying synergy and antagonism can be made. By
comparing the observed combination response with the expected
combination responses from the two models, as well as the
single drug responses, one can classify the drug combination into
five categories including strong antagonism, weak antagonism,
non-interaction, weak synergy, and strong synergy. We propose
the use of the interaction barometer to visualize the degree of
interaction on the common axis of drug response, which has been
shown to facilitate the interpretation and comparison between
different combinations. We view our efforts as a continuation
to what the Saariselkä agreement started more than 20 years
ago but has not yet concluded: a consensus on concepts and
terminology for interaction assessment. We acknowledge that
our proposal is not yet solving the practical issues for analyzing
real data which typically contain combination responses tested
at different dose ranges. How to maximize the benefits of the
interaction barometer to summarize the interaction patterns
of a drug combination would be a source of future research
initiatives. We hope that such a classification scheme will raise
more discussions about the standardization of the interaction
assessment, toward finally reaching a consensus not only on the
definition itself, but also on the other important issues, such as the
experimental design of combination experiments, their quality
control and the statistical evaluation of synergy and antagonism.
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